Q32 Bio (NASDAQ:QTTB) CFO Lee Kalowski Sells 3,972 Shares

Q32 Bio Inc. (NASDAQ:QTTB) CFO Lee Kalowski sold 3,972 shares of Q32 Bio stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $65,776.32. Following the completion of the transaction, the chief financial officer owned 138,471 shares in the company, valued at approximately $2,293,079.76. The trade was a 2.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Q32 Bio Stock Performance

Q32 Bio stock opened at $16.15 on Friday. Q32 Bio Inc. has a 52 week low of $1.62 and a 52 week high of $23.57. The stock has a market capitalization of $480.79 million, a P/E ratio of 5.38 and a beta of 0.23. The stock has a fifty day moving average of $14.84 and a 200-day moving average of $9.67.

Q32 Bio (NASDAQ:QTTB) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.02. On average, research analysts forecast that Q32 Bio Inc. will post -1.51 earnings per share for the current year.

Wall Street Analyst Weigh In

QTTB has been the topic of several research reports. Mizuho initiated coverage on shares of Q32 Bio in a report on Friday, May 22nd. They set an “outperform” rating and a $14.00 price target on the stock. Oppenheimer raised their target price on shares of Q32 Bio from $20.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Zacks Research lowered shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. HC Wainwright increased their price target on Q32 Bio from $13.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Finally, Weiss Ratings upgraded Q32 Bio from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 21st. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in QTTB. HRT Financial LP raised its holdings in Q32 Bio by 66.5% in the 4th quarter. HRT Financial LP now owns 24,698 shares of the company’s stock valued at $81,000 after buying an additional 9,862 shares during the last quarter. ADAR1 Capital Management LLC grew its holdings in Q32 Bio by 75.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 35,000 shares of the company’s stock worth $225,000 after acquiring an additional 15,000 shares during the last quarter. Marshall Wace LLP acquired a new position in Q32 Bio in the 2nd quarter valued at approximately $25,000. Geode Capital Management LLC raised its stake in shares of Q32 Bio by 19.9% during the fourth quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock valued at $352,000 after acquiring an additional 17,617 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Q32 Bio during the fourth quarter valued at $68,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.